The ASAM National Practice Guideline 2020 Focused Update Webinar Series

4.75 (4 votes)

  • Register
    • Non-Member - $175
    • Regular Member - Free!
    • Retired - Free!
    • Early Career Physician - Free!
    • Resident - Free!
    • Student - Free!
    • Associate - Free!
    • ASAM Staff - Free!
    • International Member - Free!
    • Emeritus Member - Free!
    • Provisional Member - Free!
    • Fellow Member - Free!
    • Honorary Member - Free!
    • CRT Member - Free!

image

The ASAM National Practice Guideline 2020 Focused Update Webinar Series


Opioid use disorder is a chronic, relapsing disease, which has significant economic, personal, and public health consequences. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use was developed to assist in the evaluation and treatment of opioid use disorder. Topics covered included: opioid withdrawal management, psychosocial treatment, special populations, and opioid overdose. The ASAM Guideline was the first guideline to address all medications available in the U.S. for the treatment of opioid addiction and overdose, in a single document. Since its publication in 2015, new medications and science in the field emerged, compelling ASAM to conduct a focused update.

This 5-part webinar series discusses the ASAM National Practice Guideline 2020 Focused Update. Topics include the fundamentals of the guideline update, and topics specific to pregnant women, opioid use disorder and pain, individuals in the Criminal Justice System, and adolescents and young adults. This webinar series is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level. 

All webinars in the series will be free for ASAM members to join live and watch the recorded on-demand session. For non-ASAM members, it will be free to join live and watch on-demand webinars for 30-days after the live webinar date. Following the 30 days, non-ASAM members can purchase the on-demand webinars for $39 each or at a discounted price for the entire 5-webinar package. The first webinar focused on the Fundamentals will continue to be free for everyone. 

Webinar Series Topics & Dates

  1. Fundamentals: Tuesday, May 26, 2020; 12:00 pm ET
  2. Pregnant Women: Tuesday, June 30, 2020; 2:00 pm ET
  3. OUD and Pain: Tuesday, July 21, 2020; 1:00 pm ET
  4. Individuals in the Criminal Justice System: Thursday, September 10, 2020; 12:00 pm ET
  5. Adolescents and Young Adults: Tuesday, September 24, 2020; 1:00 pm ET

  • The ASAM National Practice Guideline 2020 Focused Update Webinar – Adolescents & Young Adults

    Contains 4 Component(s), Includes Credits

    This session will provide an overview of the new and updated recommendations and in-depth information on treating youth with OUD from the ASAM National Practice Guideline.

    image

    The ASAM National Practice Guideline 2020 Focused Update Webinar – Adolescents & Young Adults


    This webinar follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals webinar, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder

    Adolescents and young adults present for treatment with a broad spectrum of opioid use disorder severity with a range of co-occurring medical and psychiatric illnesses. The treatment of youth with opioid use disorder presents many unique medical, legal, and ethical dilemmas that may complicate treatment. Given these unique issues, adolescents and young adults often benefit from services designed specifically for them. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating youth with OUD from the ASAM National Practice Guideline.

    Session Information 

    Date: Live webinar on Thursday, September 24, 2020, this session is now available on-demand as a recorded webinar

    Speaker(s): Marc Fishman, MD

    Learning Objectives 

    By completing this webinar, you will be able to:

    1. Summarize the guideline’s treatment recommendations for adolescents and young adults with OUD and discuss how they should be used in practice. 
    2. Identify the fundamental components of an OUD patient assessment and diagnosis for adolescents and young adults.
    3. Recognize the unique needs and treatment recommendations for adolescents and young adults

    Marc Fishman

    MD

    Marc Fishman MD is a specialist in  addiction psychiatry and addiction medicine.  He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of drug-involved and dual-diagnosis adolescents and adults. He has written and lectured widely on a variety of topics including youth treatment, placement and treatment matching strategies, co-occurring disorders, and medication treatment for addiction. His research focus has been in treatment of opioid use disorders in youth. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine, and a current memeber of its Board.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

    Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

    Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

    George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

    Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

    Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

    Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures


  • The ASAM National Practice Guideline 2020 Focused Update Webinar – Individuals in the Criminal Justice System

    Contains 4 Component(s), Includes Credits

    This session will provide an overview of the new and updated recommendations and in-depth information on treating individuals in the criminal justice system from the ASAM National Practice Guideline.

    image

    The ASAM National Practice Guideline 2020 Focused Update Webinar – Individuals in the Criminal Justice System


    This webinar follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals webinar, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder

    A substantial proportion of persons in prisons, jails, drug courts, probation, parole, and who are criminally involved have opioid use disorder and related problems. The high concentration of at-risk individuals and conditions of incarceration can increase the risk of adverse consequences associated with drug use, including violence, medical and psychiatric co-morbidity, drug-related deaths, self-harm and suicide. Furthermore, treatment of OUD in CJ settings has all too often been sub-standard. For example, when individuals are released from incarceration without OUD treatment, they are at extreme risk of relapse overdose and death. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating individuals in the criminal justice system from the ASAM National Practice Guideline.

    Session Information 

    Date: Live webinar on Thursday, September 10, 2020, this session is now available on-demand as a recorded webinar

    Speaker(s): Sandra Springer, MD

    Learning Objectives 

    By completing this webinar, you will be able to:

    1. Summarize the guideline’s treatment recommendations for individuals in the criminal justice system with OUD and discuss how they should be used in practice.
    2. Identify the fundamental components of an OUD patient assessment and diagnosis for individuals in the criminal justice system.
    3. Recognize the unique needs and treatment recommendations for individuals in the criminal justice system

    Sandra Springer

    MD

    Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. Dr. Springer is Board-Certified in Internal Medicine, Infectious Diseases and Addiction Medicine. In addition, she is the Director of the Infectious Disease Clinic at the Newington site of the VA Connecticut Healthcare System where she oversees the care of Veterans living with HIV (VLH). She graduated from Harvard University, then later received her Medical Degree from University of Massachusetts Medical School. She did her Internal Medicine Residency and Infectious Disease Fellowship at Yale School of Medicine. Dr. Springer has significant clinical and research experience with persons living with HIV disease (PLH) and those with comorbid substance use disorders (SUD). Her research has focused on evaluation of integration of SUD and HIV treatments. In particular, she has focused on medication treatment for opioid use disorder (OUD) (MOUD) and medication treatment for alcohol use disorders (AUD) to improve substance use relapse outcomes and HIV treatment outcomes, especially among those released from prison and jail. Dr. Springer has been continuously NIH funded for over 15 years. She has a K02 Independent Scientist Award from NIDA evaluating medication treatment for OUD (MOUD) interventions among PLH. Dr. Springer has been a buprenorphine provider since 2005, and performed the first evaluation of the use of buprenorphine to prevent relapse to opioid use and improve HIV viral suppression among PLH released from prison. She created and later validated a rapid opioid dependency screen (RODS) that quickly identifies if someone has a moderate to severe opioid use disorder (OUD) to quickly initiate MOUD. She has studied extended-release naltrexone (XR-NTX) as a PI on a 5 year NIAAA-funded R01 which used a RCT design to evaluate its effect on improving HIV viral suppression for PLH released from prison; and she was a PI on a NIDA-funded R01 within the Seek Test Treat and Retain (STTR) Criminal Justice System (CJS) consortium to evaluate the use of XR-NTX to improve HIV VS among PLH with OUD released from prison/jail.  Dr. Springer was a working group member of the NIDA STTR consortium that harmonized outcomes across 23 NIDA-funded STTR studies involving PLH and those who are at risk for HIV. Additionally, she was co-I on 2 NIDA R01s (1) using Buprenorphine to improve HIV treatment outcomes among CJS-involved PLH with OUD in Washington, D.C.; and (2) implementing XR-NTX among PLH with OUD in Ukraine. She is currently co-PI on a 5-year R01 from NIDA evaluating the impact of HIV infection on immunologic, transcriptomic, and metabolomic signatures among PLH compared to those without HIV infection who are beginning MAT for OUD. She is a co-PI with Drs. Ho and Kluger at Yale for a NIDA funded R33/R61 that is specifically evaluating the impact of all forms of MAT on HIV persistence; and she is a co-I on a HEALing NIDA funded grant to combat Opioid addiction in NY State. She is also the contact PI of a new U01 from NCATS that will integrate ID and injectable buprenorphine in hospitalized patients. She also is a co-PI on a new Justice involved HEALing grant at the NYU site with Dr. Josh Lee from NIDA evaluating OUD medication treatment for criminal justice involved persons with OUD and co-PI with Dr. Ismene Petrakis for a VA COOP grant among 900 Veterans with OUD comparing injectable and sublingual buprenorphine. She is a member of IDSA and HIVMA’s expert panel to integrate ID and OUD, a NASEM committee member evaluating the integration of ID and OUD treatment and prevention in community settings nationally, and a member of the ASAM committee that provided updated recommendations for use of MOUD in 2020. 

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

    Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

    Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

    George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

    Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

    Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

    Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures


  • The ASAM National Practice Guideline 2020 Focused Update Webinar – OUD and Pain

    Contains 4 Component(s), Includes Credits

    This session will provide an overview of the new and updated recommendations and in-depth information on treating pain in individuals with Opioid Use Disorder from the ASAM National Practice Guideline.

    image

    The ASAM National Practice Guideline 2020 Focused Update Webinar – OUD and Pain


    This webinar follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals webinar, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder

    Acute and chronic pain is common in opioid use disorder. Pain is an important factor in non-adherence to treatment in Opioid Use Disorder (OUD). In the context of the current epidemic of nonmedical prescription drug use, knowledge of safe and effective pain management is critical for the practitioner. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating pain in individuals with OUD from the ASAM National Practice Guideline.

    Session Information 

    Date: Live webinar on Tuesday, July 21, 2020, this session is now available on-demand as a recorded webinar

    Speaker(s): Timothy Wiegand, MD, FACMT, FAACT, FASAM

    Learning Objectives 

    By completing this webinar, you will be able to:

    1. Summarize the guideline’s treatment recommendations for individuals with pain & OUD & how they should be used in practice.
    2. Identify the fundamental components of an OUD patient assessment and diagnosis for individuals with pain.
    3. Recognize the unique needs and treatment recommendations for individuals with pain

    Timothy J. Wiegand

    MD, FACMT, FAACT, FASAM

    Tim Wiegand MD, DABAM, FACMT, FAACT was trained in internal medicine and completed fellowship training in Medical Toxicology at the University of California, San Francisco in 2006. He was the Medical Director of the Rochester Poison Center until 2010. Dr. Wiegand has been successful in developing a full time, bedside, medical toxicology consultation service and is very active in the practice of Addiction Medicine, having successfully completed his board certification recently. 

    In addition to his primary appointment as Associate Professor of Emergency Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, NY, Dr. Wiegand serves as Medical Director for Huther Doyle Chemical Dependency Treatment Program in Rochester, NY and as a detoxification specialist for Syracuse Behavioral Health in Rochester, NY. 

    Dr. Wiegand serves on the New York Society of Addiction Medicine (NYSAM) Board of Directors as the Communication Committee Chair and he was recently elected to the American College of Medical Toxicology Board of Directors to begin a 3 year term in October, 2015. He currently serves as the chair of the Addiction Medicine Section for the American College of Medical Toxicology and he recently organized a very successful Addiction Medicine Academy for ACMT prior to their main Annual Scientific Meeting in Clearwater, Florida in March, 2015. Dr. Wiegand has presented for the ASAM Review Course on Pharmacology & Toxicology, MRO and drug testing principles at previous Review Course conferences.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

    Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

    Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

    George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

    Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

    Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

    Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures


  • The ASAM National Practice Guideline 2020 Focused Update – Pregnant Women

    Contains 4 Component(s), Includes Credits

    This session will provide an overview of the new and updated recommendations and in-depth information on treating pregnant women from the ASAM National Practice Guideline.

    image

    The ASAM National Practice Guideline 2020 Focused Update – Pregnant Women


    This session follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals session, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder

    Many of the risks associated with opioid use disorder are similar for both pregnant and non-pregnant women. However, opioid use disorder carries additional risks for pregnant women and prenatal risk for the developing fetus. Treatment of pregnant women with MOUD is associated with substantial improvement in outcomes for both mother and child. This session will provide an overview of the new and updated recommendations and in-depth information on treating pregnant women from the ASAM NPG.

    Session Information 

    Date: Live webinar on Tuesday, June 30, 2020, this session is now available on-demand as a recorded webinar

    Speaker(s): Tricia Wright, MD, MS, FACOG, FASAM

    Learning Objectives 

    By completing this webinar, you will be able to:

    1. Summarize the guideline’s treatment recommendations for the mother-infant dyad and discuss their practical implications. 
    2. Identify the fundamental components of an OUD patient assessment and diagnosis for pregnant and postpartum women.
    3. Recognize the unique needs and treatment recommendations for pregnant and postpartum women.

    Tricia Wright

    MD, MS, FACOG, FASAM

    Tricia Wright, MD, MS recently moved to California from Hawai‘i to become a Professor of Obstetrics, Gynecology and Reproductive Sciences at UCSF. She is board certified in both Obstetrics and Gynecology and Addiction Medicine and a Fellow of the American College of Obstetrics and Gynecology and a Distinguished Fellow of the American Society of Addiction Medicine. She has published multiple papers on pregnancy and addiction as well as a textbook Opioid Use Disorders in Pregnancy published in 2018 by Cambridge University Press. 

    Dr. Wright completed her undergraduate degree in Biological Sciences from Stanford University, her MD from the University of Michigan. She completed her residency in Obstetrics and Gynecology from the University of New Mexico and obtained a Master’s Degree in Clinical Research from the University of Hawai‘i. 

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

    Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

    Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

    George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

    Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

    Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

    Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures


  • The ASAM National Practice Guideline 2020 Focused Update – Fundamentals

    Contains 4 Component(s), Includes Credits

    The first of its series, this webinar outlines the highlights of the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder, focusing on the several new buprenorphine formulations recently approved by the FDA.

    image

    The ASAM National Practice Guideline 2020 Focused Update – Fundamentals


    Opioid use disorder is a chronic, relapsing disease, which has significant economic, personal, and public health consequences. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use was developed to assist in the evaluation and treatment of opioid use disorder. Topics covered included: opioid withdrawal management, psycho-social treatment, special populations, and opioid overdose. The ASAM Guideline was the first guideline to address all medications available in the U.S. for the treatment of opioid addiction and overdose, in a single document. Since its publication in 2015, new medications and science in the field emerged, compelling ASAM to conduct a focused update. 

    The first of its series, this webinar outlines the highlights of the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder, focusing on the several new buprenorphine formulations recently approved by the FDA.    

    Session Information

    Date: Live webinar on Tuesday, May 26, 2020, this session is now available on-demand as a recorded webinar

    Speaker(s): Kyle Kampman, MD

    Learning Objectives

    By completing this session, you will be able to:

    • 1. Summarize the guideline’s treatment recommendations and discuss how they should be used in practice.
    • 2. Recognize the changing epidemiology of opioid use disorder and the remaining gaps in the treatments of OUD. 
    • 3. Describe the new buprenorphine formulations including generic and brand names, route of administration, dosing, and clinical considerations.  

    Dr. Kyle M. Kampman, MD

    Professor, Perelman School of Medicine

    Dr. Kyle Kampman graduated from Northwestern University in 1981 and Tulane University School of Medicine in 1985. He interned at the National Naval Medical Center at Bethesda Maryland and served in the United States Navy from 1985 until 1990. He came to the University of Pennsylvania and served as a resident in psychiatry from 1990 until 1993. He then completed a fellowship in Addiction Psychiatry. In 1994 he joined the faculty in the Department of Psychiatry as an assistant professor. He was promoted to associate professor in 2003 and to professor in 2012. Dr. Kampman has had extensive experience in the treatment of alcohol cocaine and opiate dependence. He has conducted a number of trials testing medications for the treatment of cocaine alcohol and opiate dependence and is a recognized authority on the cocaine withdrawal syndrome. In addition to research, he works at the Addiction Recovery Unit of the Philadelphia VA Medical Center where he continues to treat cocaine, alcohol and opiate dependent patients with both medications and psychotherapy.

    Credits and Disclosures


    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet course for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification


    American Board of Preventive Medicine (ABPM)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    American Board of Anesthesiology (ABA)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    American Board of Pediatrics (ABP)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC point in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    American Board of Addiction Medicine (ABAM)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    CME Reviewer and Disclosure Information


    ASAM CME Committee Reviewer

    Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Faculty and Panelists


    Kyle M. Kampman, MD – Does Disclose
    World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

ACCME Accredited with Commendation

CME/CE Credits

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NAADAC, the Association for Addiction Professionals

This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205

Continuing Education Credits (CEUs)

Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification (MOC)

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 5 LLSA credit towards ABPM MOC Part II requirements.

ABA Maintenance of Certification (MOC)

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

ABP Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

 ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABAM Transitional Maintenance of Certification (Tmoc)

Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

American Board of Psychiatry and Neurology (ABPN)

Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

Program Planning Committee, CME Committee, Medical Education Council (MEC)

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

ASAM CME Committee Reviewer

Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

Faculty & Planning Committee Disclosures

Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures